Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07799740

Examination of Rectal Blood Supply During Rectal Cancer Surgery Using Laser Speckle Contrast Imaging

This multicentre feasibility study evaluates the feasibility of performing laparoscopic Laser Speckle Contrast Imaging (LSCI) measurements of rectal perfusion during rectal cancer surgery. To our knowledge, LSCI has not previously been applied laparoscopically for intraoperative assessment of rectal perfusion in this setting. Laparoscopic LSCI measurements will be compared with indocyanine green fluorescence imaging, and associations between quantitative measures of colorectal perfusion and postoperative outcomes, including anastomotic leakage, will be explored.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Regional Hospital Gødstrup, Herning, Denmark

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • Rectal cancer
  • Surgical strategy either partial or total mesorectal excision
  • Able to provide informed consent

Exclusion criteria

  • Allergy to iodine

Treatment and study plan

Laser speckle contrast imaging

Device

Investigated device: PerfusiX-Imaging, LIMIS Development B.V., The Netherlands ICG-FI: Verdye, 0.2 mg/kg, Firefly® fluorescence imaging

PerfusiX-Imaging is used Intracorporally prior to anal specimen transection, extracoporally prior to oral speciamen transection, intracorporally assessing the free bowel ends prior to anastomotic formation. ICG-FI is applied intracorporally assessing the free bowel ends prior to anastomotic formation.

Diagnostic imaging: All participants undergo computed tomography with intravenous contrast and a rectal contrast enema.

Primary outcomes

  1. Technical feasibility of intraoperative microcirculation assessment using PerfusiX-Imaging

    Time frame: Intraoperatively

    Feasibility is considered demonstrated if time spent on PerfusiX-Imaging measurements is ≤ 5% of total operating time and no more than two measurements are required to obtain a sufficient assessment of intestinal microcirculation.

    Unit:

    Percentage of participants with succesful assessment

  2. Surgeon-reported acceptability of PerfusiX-Imaging

    Time frame: intraoperatively

    Surgeons will assess the acceptability and performance of PerfusiX-Imaging using a predefined Likert-scale questionnaire. Feasibility will be considered demonstrated if >80% of surgeons report a positive evaluation of PerfusiX-Imaging. A positive evaluation is defined as a Likert score of ≥ 4 on at least three of the four predefined evaluation questions.

    Unit:

    Percentage of surgeons with a positive evaluation

  3. Potential impact of PerfusiX-Imaging on surgical decision making

    Time frame: Intraoperatively

    The distance between the marked oral transection line with and without the use of PerfusiX-Imaging given by the surgeon and an independent expert. Feasibility will be considered demonstrated if the transection line differs by ≥ 10 mm.

    Unit: milimetres (mm)

Secondary outcomes

  1. Comparison of surgeon-reported acceptability between PerfusiX-Imaging and ICG-FI

    Time frame: Immediately after surgery

    Surgeons will assess the acceptability and performance of PerfusiX-Imaging and ICG-FI using a predefined Likert-scale questionnaire. A positive evaluation is defined as a Likert score of ≥ 4 on at least three of the four predefined evaluation questions. The proportion of surgeons providing a positive evaluation of PerfusiX-Imaging will be compared with the proportion providing a positive evaluation on ICG-FI.

    Unit of measure:

    Proportion of surgeons

  2. Absolute intestinal microcirculation

    Time frame: Intraoperatively

    Intestinal microcirculation will be quantified using laser speckle contrast imaging (LSCI). Absolute microcirculation will be expressed as the mean laser speckle perfusion unit (LSPU) value obtained from a predefined region of interest (ROI) close to the intestinal anastomotic line.

    Unit of measure:

    Laser speckle perfusion units, LSPU

  3. Relative intestinal microcirculation

    Time frame: Intraoperatively

    Relative intestinal microcirculation will be calculated by normalizing the mean LSPU value from a region of interest to the mean LSPU value obtained from a reference region on the intestines:

    Unit of measure:

    Percentage (%): measurement/control*100

  4. Length of initial hospital stay after surgery

    Time frame: From the end of surgery until initial hospital discharge, up to 30 days after surgery

    Length of initial hospital stay after surgery will be calculated as the number of hours from the end of surgery until initial discharge from hospital. The association between length of initial hospital stay after surgery and quantitative measurements of intestinal microcirculation will be explored.

    Unit of measure:

    Hours

  5. Severity of postoperative complications according to the Clavien-Dindo classification

    Time frame: 30 days after surgery

    Postoperative complications occuring within 30 days after surgery will be graded according to the Clavien-Dindo classification (Grade I-V). The asociation between quatitative measurements of intestinal microcirculation and the severity of postoperative complications will be explored.

    Units of measure:

    Clavien-Dindo

  6. Surgical complications within 30 days after surgery

    Time frame: 30 days after surgery

    The occurence of surgical complications within 30 days after surgery will be recorded. Surgical complications include bleeding, fascial dehiscence, postoperative ileus, surgical site infection, intraabdominal abscess, stoma related complications. The association between surgical complications within 30 days after surgery and quantitative measurements of intestinal microcirculation will be explored.

    Units of measure:

    Participants with one or more surgical complications

  7. Medical complications within 30 days after surgery

    Time frame: 30 days after surgery

    The occurence of medical complications within 30 days after surgery will be recorded. Medical complicatinos include stroke, myocardial infarction, heart failure, pneumonia, aspiration, respiratory failure, deep vein thrombosis, acute arterial insufficiency and sepsis. The association between medical complications within 30 days after surgery and quantitative measurements of intestinal microcirculation will be explored

    Units of measure:

    Participants with one or more medical complications

  8. Anastomotic leakage within 30 days of surgery

    Time frame: 30 days after surgery

    Occurrence of anastomotic leakage within 30 days after surgery will be recorded as a binary outcome (yes/no). The association between anastomotic leakage and quantitative measurements of intestinal microcirculation will be explored.

    Units of measure:

    Participants with anastomotic leakage

Study contacts

Contact information is provided by the study sponsor or research team.

Mai-Britt W. Ørntoft, MD, Ph.D, Ass. Professor

CONTACT

[email protected]

+45 61670561

Sponsors and collaborators

Lead sponsor

University of Aarhus

Other

Collaborators

  • Gødstrup Hospital
  • Vejle Hospital

Registry information

Official study title

Laser Speckle Contrast Imaging for Rectal Anastomotic Evaluation (LIRA): A Feasibility Study.

Acronym: LIRA

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Sep 2, 2026
Registry last updated
Sep 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.